A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.Read more
RenovoRx is trying to make cancer treatment more precise by delivering medicine directly to hard-to-treat tumors, and more hospitals may start using its approach as targeted, less invasive care becomes more common. The big swing factor is whether an upcoming late-stage study supports broader use and better pricing—or whether slow uptake, delays, and the need to raise more cash hold it back.Read more
Catalysts About RenovoRx RenovoRx is a medical technology company focused on targeted intra-arterial drug delivery for treating solid tumors, including locally advanced pancreatic cancer. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About RenovoRx RenovoRx develops and commercializes TAMP enabled by the RenovoCath device for targeted intra-arterial delivery of chemotherapy to solid tumors. What are the underlying business or industry changes driving this perspective?Read more
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
